الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 141 |  |  |
| | | from | 141 | | |
Abstract
PD-L1 (programmed death-ligand 1) expression in colorectal carcinoma and its relationship with clinicopathologic factors Aim of the Work: Studying istopathological features of colorectal cancer, detection of immunohistochemical (IHC) expression of PD-L1 by tumor cells, correlation of this expression with the clinico-pathologic parameters of the tumors and value of anti-PD-L1 immunotherapy in treatment of CRC. Material and Methods: This is a retrospctive study conducted on formalin-fixed, paraffin embedded (FFPE) tissues of colorectal carcinoma cases using tissue microarray approach of 97 cases out of 114 cases retrieved from the archive of the surgical pathology lab at the Gastrointestinal Surgery Center (GISC) of Mansoura University. After demographic and clinicopathological collection, histopathological evaluation was done for CRC typing and staging. IHC was performed for PD-L1. Results: PD-L1 was expressed in 61% of CRCs. On analysis of the PD-L1 expression in relation to clinicopathological features of the tumors, its positivity was not significantly correlated with age, gender, TNM stage and tumor size, but showed a significant positive correlation with tumor grade, LVI & lymph node metastasis.On analysis of PD-L1 expression in TILs, 41.2% of cases in our study were positive for PD-L1 in TILs. We encountered a significant positive correlation between PD-L1 positivity in TILs and lower tumor grade, tumor stage, LN metastasis, distant metastasis, TNM stage and LVI invasion. Conclusion: Findings from the current study suggested that tumor cell PD-L1 expression is considered as a poor prognostic marker for colorectal cancer,whereas TILs PD-L1 expression was associated with favorable pathological parameters, therefore, expression of PD-L1 can be used as abiomarker to predict the prognosis of colon cancer. Key Words ( not more than 10 ) Programmed Death-Ligand 1- colorectal cancer- immunotherapy- TILs